Chimerix Inc (CMRX) CEO Purchases $104,400.00 in Stock

Chimerix Inc (NASDAQ:CMRX) CEO Michael A. Sherman purchased 30,000 shares of the business’s stock in a transaction on Monday, May 20th. The shares were acquired at an average price of $3.48 per share, with a total value of $104,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Chimerix stock traded down $0.09 during trading on Monday, reaching $3.41. 394,143 shares of the stock were exchanged, compared to its average volume of 487,432. Chimerix Inc has a 1 year low of $1.74 and a 1 year high of $5.04. The firm has a market cap of $174.66 million, a P/E ratio of -2.38 and a beta of 1.47.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.35). Chimerix had a negative net margin of 757.77% and a negative return on equity of 36.85%. The company had revenue of $2.36 million during the quarter, compared to the consensus estimate of $2.00 million. Sell-side analysts anticipate that Chimerix Inc will post -1.18 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Investments LP raised its stake in Chimerix by 52.9% in the fourth quarter. Two Sigma Investments LP now owns 308,732 shares of the biopharmaceutical company’s stock worth $793,000 after buying an additional 106,750 shares in the last quarter. Rhumbline Advisers raised its stake in Chimerix by 45.7% in the fourth quarter. Rhumbline Advisers now owns 65,845 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 20,654 shares in the last quarter. Morgan Stanley raised its stake in Chimerix by 28.8% in the third quarter. Morgan Stanley now owns 2,041,150 shares of the biopharmaceutical company’s stock worth $7,940,000 after buying an additional 456,290 shares in the last quarter. Pitcairn Co. bought a new position in Chimerix in the fourth quarter worth about $42,000. Finally, Deutsche Bank AG raised its stake in Chimerix by 27.7% in the fourth quarter. Deutsche Bank AG now owns 258,033 shares of the biopharmaceutical company’s stock worth $662,000 after buying an additional 55,950 shares in the last quarter. 70.83% of the stock is owned by institutional investors.

A number of research firms have recently weighed in on CMRX. Zacks Investment Research upgraded shares of Chimerix from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a report on Wednesday, May 15th. Cowen reiterated a “hold” rating and set a $3.00 target price on shares of Chimerix in a report on Thursday, May 9th. ValuEngine lowered shares of Chimerix from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. HC Wainwright reiterated a “buy” rating on shares of Chimerix in a report on Wednesday, February 6th. Finally, Citigroup dropped their target price on shares of Chimerix from $4.25 to $2.00 and set a “neutral” rating for the company in a report on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. Chimerix presently has an average rating of “Hold” and an average price target of $4.75.

TRADEMARK VIOLATION WARNING: “Chimerix Inc (CMRX) CEO Purchases $104,400.00 in Stock” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/05/20/chimerix-inc-cmrx-ceo-purchases-104400-00-in-stock.html.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Read More: What is Cost of Goods Sold (COGS)?

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.